Did You Know...
...that power steering was invented by independent inventor Francis W. Davis? As chief engineer in the 1920s of the truck division of the Pierce Arrow Motor Car Company, he saw how hard it was to steer heavy vehicles. So that he would be able to keep the profits from his future invention, Davis left his job, rented a small engineering shop in Waltham, Mass., and developed a hydraulic power steering system that led to power steering.
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Application No. | Application Title | Issue Date |
| 20110281954 | METHODS OF SYNTHESIZING CINACALCET AND SALTS THEREOF Methods of preparing cinacalcet, cinacalcet derivatives, and salts thereof is disclosed herein. Also disclosed herein are polymorphs of cinacalcet, compositions of cinacalcet, and methods of treating a subject by administering cinacalcet, wherein cinacalcet is prepared ... | 11/17/2011 |
| 20110274691 | FERROPORTIN ANTIBODIES AND METHODS OF USE Compositions for treating disorders of iron homeostasis are provided. More particularly, anti-ferroportin antibodies, compositions containing such antibodies, corresponding nucleic acids, vectors and host cells, and methods of making such antibodies are provided.... | 11/10/2011 |
| 20120010256 | INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 The present invention relates to compounds with the formula (I), (II), (III) or (IV):
| 01/12/2012 |
| 20110294837 | Aurora Kinase Modulators and Methods of Use The present invention relates to chemical compounds having a general formula I wherein A1-6, L1, R1, R4-6 and n are defined herein, and synthetic intermediates, whi... | 12/01/2011 |
| 20110230517 | CALCIUM RECEPTOR MODULATING AGENTS The present invention relates generally to novel calcimimetic compounds and pharmaceutical compositions comprising them. The invention also relates to methods of treating of diseases or disorders related to the function of the calcium sensing receptor using the compound... | 09/22/2011 |
| 20110165580 | Response Element Regions Response element regions, DNA constructs comprising response element regions, host cells comprising response element regions, and methods of using response element regions are provided.... | 07/07/2011 |
| 20110160463 | PROCESS FOR MAKING SUBSTITUTED 2-AMINO-THIAZOLONES The present invention relates to methods of making compounds that inhibit 11-β-hydroxysteroid dehydrogenase type 1 enzyme (11-β HSD1). One method comprises (a) contacting a compound of formula (II) with a chiral base, deprotonating agent, and an alkylating agent R 06/30/2011 | |
| 20110144102 | CALCIMIMETIC COMPOUND FOR USE IN THE TREATMENT OF EPITHELIAL INJURY This invention relates generally to the field of medicine and, more specifically, to methods for treating epithelial injury, in particular, due to ischemia, hypoxia, trauma, chemolytics or radiation exposure.... | 06/16/2011 |
| 20110136915 | RAPID DISSOLUTION FORMULATION OF A CALCIUM RECEPTOR-ACTIVE COMPOUND The present invention relates to a pharmaceutical composition comprising a therapeutically effective amount of a calcium receptor-active compound and at least one pharmaceutically acceptable excipient, wherein the composition has a controlled dissolution profile. The pr... | 06/09/2011 |
| 20110092504 | INHIBITORS OF PI3 KINASE The present invention relates to compounds of Formula (I), or a pharmaceutically acceptable salt thereof; methods of treating diseases or conditions, such as cancer, using the compounds; and pharmaceutical compositions containing the compounds, wherein Q, X1,... | 04/21/2011 |
| 20110082107 | INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 The present invention relates to compounds with the formula (I), (II), (III) or (IV):
| 04/07/2011 |
| 20110070615 | Compositions and Methods Relating to Anti-IGF-1 Receptor Antibodies The present invention provides compositions and methods relating to or derived from anti-IGF-1R antibodies. In particular embodiments, the invention provides fully human, humanized, or chimeric anti-IGF-1R antibodies that bind human IGF-1R, IGF-1R-binding fragments and ... | 03/24/2011 |
| 20110059068 | POLYPEPTIDES INVOLVED IN IMMUNE RESPONSE Polypeptides which comprise a receptor-ligand pair involved in T-cell activation are disclosed. Nucleic acid molecules encoding the polypeptides, and vectors and host cells for expressing the polypeptides are also disclosed. The polypeptides, or agonists and antagonists... | 03/10/2011 |
| 20110044978 | METHOD FOR TREATING BONE FRACTURE The invention provides a method of enhancing bone fracture healing involving administering a sclerostin inhibitor. In one aspect, the invention includes use of a therapeutically effective amount of sclerostin binding agent to treat a bone fracture, wherein one or more a... | 02/24/2011 |
| 20110008375 | Uses of Myostatin Antagonists The present invention provides methods for treating disorders arising from hypogonadism, rheumatoid cachexia, cachexia due to burns, cachexia due to administration of chemical agents, cachexia due to diabetes, diabetic nephropathy, Prader Willi syndrome, excessive TNF-Î... | 01/13/2011 |
| 20100316593 | Pharmaceutical Formulations A method of stabilizing an aqueous protein or antibody formulation is disclosed herein. Additionally, stable pharmaceutical formulations are contemplated which comprise a biologically active protein, a destabilizing concentration of preservative and a stabilizing concen... | 12/16/2010 |
| 20100298367 | Conformationally Constrained Carboxylic Acid Derivatives Useful for Treating Metabolic Disorders The present invention provides compounds useful, for example, for treating metabolic disorders in a subject. Such compounds have the general formula I or the general formula III: where the definitions of the ... | 11/25/2010 |
| 20100298341 | Glycine Transporter-1 Inhibitors The present invention provides compounds that are glycine transporter 1 (hereinafter referred to as GlyT-1) inhibitors and are therefore useful for the treatment of diseases treatable by inhibition of GlyT1 such as cognitive disorders associated with Schizophrenia, ADHD... | 11/25/2010 |
| 20100298229 | OSTEOPROTEGERIN The present invention discloses a novel secreted polypeptide, termed osteoprotegerin, which is a member of the tumor necrosis factor receptor superfamily and is involved in the regulation of bone metabolism. Also disclosed are nucleic acids encoding osteoprotegerin, pol... | 11/25/2010 |
| 20100279323 | METHOD FOR PREDICTING RESPONSE TO EPIDERMAL GROWTH FACTOR RECEPTOR-DIRECTED THERAPY This invention provides methods for determining or predicting response to cancer therapy in an individual.... | 11/04/2010 |
| 20100267936 | PROCESS FOR CORRECTION OF A DISULFIDE MISFOLD IN Fc MOLECULES The present invention concerns a process by which a misfold in an Fc fusion molecule can be prevented or corrected. In one embodiment, the process comprises (a) preparing a pharmacologically active compound comprising an Fc domain; (b) treating the fusion molecule with ... | 10/21/2010 |
| 20100255537 | NUCLEIC ACID MOLECULES ENCODING BETA-LIKE GLYCOPROTEIN HORMONE POLYPEPTIDE AND HETERODIMER THEREOF Novel β10 polypeptides and heterodimers thereof, and nucleic acid molecules encoding the same are disclosed. The invention also provides vectors, host cells, selective binding agents, and methods for producing β10 polypeptides and heterodimeric forms thereof, specific... | 10/07/2010 |
| 20100240610 | QUINOLONE BASED COMPOUNDS EXHIBITING PROLYL HYDROXYLASE INHIBITORY ACTIVITY, AND COMPOSITIONS, AND USES THEREOF This invention relates to new quinolone based compounds that exhibit prolyl hydroxylase inhibitory activity. This invention also relates to methods of increasing HIF levels or activity in a subject or treating a condition associated with HIF levels or activity in a subj... | 09/23/2010 |
| 20100240590 | PEPTIDES AND RELATED MOLECULES THAT BIND TO TALL-1 The present invention concerns therapeutic agents that modulate the activity of TALL-1. In accordance with the present invention, modulators of TALL-1 may comprise an amino acid sequence Dz2Lz4 wherein z2 is an amino acid residue and z 09/23/2010 | |
| 20100240582 | Peptides and related molecules that modulate nerve growth factor activity The present invention relates to certain biologically active peptides and polypeptides which can be used as therapeutics or prophylactics against diseases or disorders linked to NGF as the causative agent. In one aspect of the present invention, pharmacologically active... | 09/23/2010 |
| 20100233169 | Methods for treating obesity using fibroblast growth factor-Like polypeptides The present invention provides novel Fibroblast Growth Factor-like (FGF-like) polypeptides and nucleic acid molecules encoding the same. The invention also provides vectors, host cells, antibodies and methods for producing FGF-like polypeptides. Also provided for are me... | 09/16/2010 |
| 20100226921 | Methods for treating obesity using Fibroblast Growth Factor-Like Polypeptides The present invention provides novel Fibroblast Growth Factor-like (FGF-like) polypeptides and nucleic acid molecules encoding the same. The invention also provides vectors, host cells, antibodies and methods for producing FGF-like polypeptides. Also provided for are me... | 09/09/2010 |
| 20100222338 | BETA-SECRETASE MODULATORS AND METHODS OF USE The present invention comprises a new class of compounds useful for the modulation of Beta-secretase enzyme activity and for the treatment of Beta-secretase mediated diseases, including Alzheimer's disease (AD) and related conditions. In one embodiment, the compounds ha... | 09/02/2010 |
| 20100197751 | COMPOSITIONS OF PEGYLATED SOLUBLE TUMOR NECROSIS FACTOR RECEPTORS AND METHODS OF PREPARING The present invention provides for improved compositions comprising a PEGsTNF-R1 which, in addition to having useful higher concentrations, demonstrate decreased viscosity (<400 cP) and improved stability.... | 08/05/2010 |
| 20100184763 | QUINOLONE BASED COMPOUNDS EXHIBITING, PROLYL HYDROXYLASE INHIBITORY ACTIVITY, AND COMPOSITIONS, AND USES THEREOF This invention relates to new quinolone based compounds that exhibit prolyl hydroxylase inhibitory activity. This invention also relates to methods of increasing HIF levels or activity in a subject or treating a condition associated with HIF levels or activity in a subj... | 07/22/2010 |
| 20100173418 | Polypeptides with Reduced Susceptibility to Oxidation and Methods of Making The present invention relates in general to polypeptides having reduced susceptibility to oxidation, methods of selecting or making the polypeptides and methods of use thereof. The polypeptides having reduced susceptibility to oxidation are modified by amino acid substi... | 07/08/2010 |
| 20100158908 | Stable Polypeptide Formulations The invention provides a formulation including a buffer having a pH less than 6.0, a divalent cation between about 5-200 mM, an excipient comprising a sugar or polyol and an effective amount of a therapeutic polypeptide. Also provided is a method of stabilizing a polype... | 06/24/2010 |
| 20100130727 | Methods and Systems for Isolating Target Molecules from Complex Solutions by Column-Chromatography Using Eluants Containing Organic Solvents Various system and method embodiments of the present invention are directed to separating target molecules from complex solutions by affinity column chromatography using organic-solvent-containing eluants. In one embodiment of the present invention, an eluant containing... | 05/27/2010 |
| 20100069447 | BENZAMIDE DERIVATIVES AND USES RELATED THERETO Benzamide derivatives of formulae I and II, and pharmaceutically acceptable salts, solvates, stereoisomers, and prodrugs thereof, and pharmaceutical compositions comprising the same, are described and have therapeutic utility, particularly in the treatment of diabetes, ... | 03/18/2010 |
| 20100062972 | TRIAZOLE COMPOUNDS AND USES RELATED THERETO The present invention provides a triazole compound of the following formula: a prodrug thereof or a pharmaceutically acceptable salt thereof. The above-mentioned triazole compound has superior HSD1 inhibitory... | 03/11/2010 |
| 20100047253 | FULLY HUMAN MONOCLONAL ANTIBODIES TO IL-13 The present invention is related to antibodies directed to IL-13 and uses of such antibodies. For example, in accordance with the present invention, there are provided human monoclonal antibodies directed to IL-13. Isolated polynucleotide sequences encoding, and amino a... | 02/25/2010 |
| 20090325880 | TNF RECEPTOR-LIKE MOLECULES AND USES THEREOF Novel MK61 polypeptides and nucleic acid molecules encoding the same. The invention also provides vectors, host cells, selective binding agents, and methods for producing MK61 polypeptides. Also provided for are methods for the treatment, diagnosis, amelioration, or pre... | 12/31/2009 |
| 20090312433 | TREATMENT OF VR1-ANTAGONIST-INDUCED INCREASE IN BODY TEMPERATURE WITH AN ANTIPYRETIC AGENT The present invention relates to a method of reducing a VR1-antagonist-induced increase in body temperature in a mammal in need thereof, comprising the step of administering an antipyretic agent to the mammal and the like.... | 12/17/2009 |
| 20090286964 | Modified Fc molecules The present invention concerns compositions of matter, for example, but not limited to, modified antibodies, in which one or more biologically active peptides are incorporated into a loop region of a non-terminal domain of an immunoglobulin Fc domain.... | 11/19/2009 |
| 20090281286 | Modified Fc molecules The present invention concerns compositions of matter, for example, but not limited to, modified antibodies, in which one or more biologically active peptides are incorporated into a loop region of a non-terminal domain of an immunoglobulin Fc domain.... | 11/12/2009 |
